Rebif and Speech disorder - a phase IV clinical study of FDA data

Summary:

Speech disorder is reported as a side effect among people who take Rebif (interferon beta-1a), especially for people who are female, 40-49 old, have been taking the drug for 1 - 6 months also take Ampyra, and have Depression.

The phase IV clinical study analyzes which people have Speech disorder when taking Rebif. It is created by eHealthMe based on reports of 60,837 people who have side effects when taking Rebif from the FDA, and is updated regularly.

What is Rebif?

Rebif has active ingredients of interferon beta-1a. It is often used in multiple sclerosis. eHealthMe is studying from 61,126 Rebif users. Check the latest studies of Rebif.

What is Speech disorder?

Speech disorder is found to be associated with 1,808 drugs and 2,279 conditions by eHealthMe. Check the latest studies of Speech disorder.

On Apr, 15, 2026

60,837 people reported to have side effects when taking Rebif.
Among them, 444 people (0.73%) have Speech disorder.

Among these 444 people:

* Approximation only. Some reports may have incomplete information.

Do you take Rebif and have Speech disorder?

- Check whether Speech disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rebif:

Rebif (61,126 reports)

Speech disorder treatments and more:

Speech disorder (62,574 reports)

How severe was Speech disorder and when was it recovered:

Speech disorder in Rebif

Expand to all the drugs that have ingredients of interferon beta-1a:

Speech disorder and drugs with ingredients of interferon beta-1a

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Rebif:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Speech disorder:

Speech disorder (1,808 drugs)

Browse all the conditions that are associated with Speech disorder:

Speech disorder (2,279 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on interferon beta-1a (the active ingredients of Rebif) and Rebif (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.